SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Doc Stone's Bierstube und Trading Room
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: M. Frank Greiffenstein who wrote (409)9/29/1998 9:12:00 AM
From: wolfdog2  Read Replies (1) of 638
 
PARS

There was as dynamite story on PARS's TBI drug, HU211, in the Wall St. Journal yesterday. (The story can be found on the PARS board) The stock was up on the report. PARS recently completed phase II trials for HU 211 and the results will be announced at a neurological conference next week. The results are very likely to be positive and the stock could have a nice pop after the presentation.

Any pull back under $2 would present an exceptional buying opportunity. The company has two FDA approved drugs for eye care and a third eye care drug should be approved in the near future.

There has been recent insider buying in the company. In addition the company recently hired a PR firm to get their story out.

This could be a live one.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News